Frankfurt - Delayed Quote EUR
Madrigal Pharmaceuticals, Inc. (YDO1.F)
272.00
+7.50
+(2.84%)
At close: 9:55:02 PM GMT+2
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
180,133
180,133
--
--
--
Cost of Revenue
6,233
6,233
--
--
--
Gross Profit
173,900
173,900
--
--
--
Operating Expense
671,775
671,775
380,496
293,571
242,482
Operating Income
-497,875
-497,875
-380,496
-293,571
-242,482
Net Non Operating Interest Income Expense
31,983
31,983
6,866
-1,779
363
Other Income Expense
--
--
--
--
273
Pretax Income
-465,892
-465,892
-373,630
-295,350
-241,846
Net Income Common Stockholders
-465,892
-465,892
-373,630
-295,350
-241,846
Diluted NI Available to Com Stockholders
-465,892
-465,892
-373,630
-295,350
-241,846
Basic EPS
-21.90
--
-19.99
-17.23
-14.63
Diluted EPS
-21.90
--
-19.99
-17.23
-14.63
Basic Average Shares
21,272.96
--
18,687.77
17,137.20
16,535.19
Diluted Average Shares
21,272.96
--
18,687.77
17,137.20
16,535.19
Total Operating Income as Reported
-497,875
-497,875
-380,496
-293,571
-242,482
Total Expenses
678,008
678,008
380,496
293,571
242,482
Net Income from Continuing & Discontinued Operation
-465,892
-465,892
-373,630
-295,350
-241,846
Normalized Income
-465,892
-465,892
-373,630
-295,350
-241,846
Interest Income
46,654
46,654
19,578
2,185
363
Interest Expense
14,671
14,671
12,712
3,964
--
Net Interest Income
31,983
31,983
6,866
-1,779
363
EBIT
-451,221
-451,221
-360,918
-291,386
-241,846
EBITDA
-450,125
-450,125
-360,391
-290,919
-241,441
Reconciled Cost of Revenue
6,233
6,233
--
--
--
Reconciled Depreciation
1,096
1,096
527
467
405
Net Income from Continuing Operation Net Minority Interest
-465,892
-465,892
-373,630
-295,350
-241,846
Normalized EBITDA
-450,125
-450,125
-360,391
-290,919
-241,441
12/31/2021 - 2/9/2007
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade